Sumitomo Mitsui Trust Holdings, Inc. Vaxcyte, Inc. Transaction History
Sumitomo Mitsui Trust Holdings, Inc.
- $134 Billion
- Q2 2024
A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 4,529 shares of PCVX stock, worth $522,238. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,529Holding current value
$522,238% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PCVX
# of Institutions
286Shares Held
110MCall Options Held
248KPut Options Held
109K-
Black Rock Inc. New York, NY9.94MShares$1.15 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.8MShares$1.13 Billion0.01% of portfolio
-
Janus Henderson Group PLC London, X08.87MShares$1.02 Billion0.37% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.2MShares$946 Million9.34% of portfolio
-
Wellington Management Group LLP Boston, MA4.59MShares$530 Million0.06% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $6.84B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...